Skip to main content
Qyuns Therapeutics Co., Ltd. logo

Qyuns Therapeutics Co., Ltd. — Investor Relations & Filings

Ticker · 2509 ISIN · CNE1000069W9 HKEX Manufacturing
Filings indexed 180 across all filing types
Latest filing 2026-05-08 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2509

About Qyuns Therapeutics Co., Ltd.

http://www.qyuns.net

Qyuns Therapeutics Co., Ltd. is a clinical-stage biopharmaceutical company specializing in the research, development, industrialization, and commercialization of antibody drugs for autoimmune and allergic diseases. The company operates an integrated platform covering the entire value chain, from proprietary antibody discovery (including a rabbit antibody development platform) to cGMP-compliant, commercial-scale internal manufacturing. Qyuns focuses on improving drug accessibility and affordability in its target areas. Its robust pipeline features 10 drug candidates targeting major inflammatory pathways, such as IL-12/IL-23p40, IL-4R , IL-17A, IL-23p19, and TSLP. The pipeline addresses four key therapeutic areas: dermatology, rheumatology, respiratory, and digestive diseases, with several assets in late-stage clinical development.

Recent filings

Filing Released Lang Actions
Documents on Display
Regulatory Filings
2026-05-08 English
NOTICE OF 2025 ANNUAL GENERAL MEETING
Regulatory Filings
2026-05-08 English
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, MAY 29, 2026
Regulatory Filings
2026-05-08 English
CIRCULAR FOR ANNUAL GENERAL MEETING
Regulatory Filings
2026-05-08 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings
2026-05-07 English
DISCLOSEABLE TRANSACTIONS IN RELATION TO SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS
Regulatory Filings Classification · 65% confidence The document is an official announcement under the Hong Kong Listing Rules regarding Qyuns Therapeutics’ discloseable transactions involving subscriptions to wealth management products. It details transaction terms, board approvals, and Listing Rules implications but does not provide financial statements or serve as an earnings report. It is not a share issue, dividend notice, or capital raise; rather, it is a regulatory announcement of specific transactions. This falls under the catch-all “Regulatory Filings” category for miscellaneous compliance disclosures that do not fit other specific filing types.
2026-04-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.